HKG: 2566

Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Fineline Cube Mar 18, 2026

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China’s...

Company Drug

Hangzhou Jiuyuan Announces NMPA Approval for Generic Doptelet in Thrombocytopenia Treatmen

Fineline Cube Jul 4, 2025

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced that it has received marketing approval...

Company Deals

Fosun Pharma and Jiuyuan Gene Partner to Commercialize Biologics in Global Markets

Fineline Cube May 29, 2025

Chinese pharmaceutical firms Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Hangzhou...

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways